| Market Cap | 2.41B 2.1B 1.95B 1.79B 3.39B 230B 3.44B 23.02B 9.04B 115B 9.07B 8.87B 385B | P/E 2026 * |
-7.93x | P/E 2027 * | -6.59x |
|---|---|---|---|---|---|
| Enterprise Value | 2.41B 2.1B 1.95B 1.79B 3.39B 230B 3.44B 23.02B 9.04B 115B 9.07B 8.87B 385B | EV / Sales 2026 * |
58.2x | EV / Sales 2027 * | 65.3x |
| Free-Float |
99.55% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Nektar Therapeutics
| 1 day | -0.71% |
| Manager | Title | Age | Since |
|---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 73 | 01/01/2007 |
Linda Rubinstein
DFI | Director of Finance/CFO | 60 | 15/05/2026 |
| Chief Tech/Sci/R&D Officer | 52 | 01/07/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Roy Whitfield
BRD | Director/Board Member | 72 | 01/08/2000 |
Robert Chess
CHM | Chairman | 69 | 01/05/1992 |
Howard Robin
BRD | Director/Board Member | 73 | 01/02/2007 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.71% | +1.97% | - | - | 2.41B | |
| +2.35% | +0.77% | +29.92% | +85.38% | 55.23B | |
| -0.21% | -6.52% | +42.39% | +64.10% | 53.75B | |
| -2.44% | -1.61% | -17.69% | -15.68% | 23.48B | |
| -2.85% | -8.20% | -6.26% | +361.83% | 22B | |
| +2.49% | -1.27% | +15.99% | -10.53% | 19.78B | |
| +0.79% | -2.39% | +26.99% | -31.34% | 17.44B | |
| +0.58% | -7.23% | +24.50% | +519.07% | 14.66B | |
| -5.25% | -4.71% | +43.89% | +167.15% | 14.07B | |
| +3.41% | -7.83% | +161.76% | +284.91% | 13.02B | |
| Average | -0.18% | -1.43% | +35.72% | +158.32% | 25.94B | |
| Weighted average by Cap. | +0.16% | +0.09% | +31.05% | +122.81% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 41.44M 36.03M 33.53M 30.79M 58.14M 3.96B 59.04M 395M 155M 1.97B 156M 152M 6.6B | 36.99M 32.15M 29.93M 27.48M 51.89M 3.53B 52.69M 353M 138M 1.76B 139M 136M 5.89B |
| Net income | -249M -217M -202M -185M -350M -23.78B -355M -2.38B -933M -11.84B -936M -915M -39.7B | -351M -305M -284M -261M -492M -33.49B -500M -3.35B -1.31B -16.67B -1.32B -1.29B -55.9B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
